代表性论文

BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis, Signal Transduction and Targeted Therapy, 2026 Apr 8;11(1):125.

Discovery of IHMT-15130 as a Highly Potent Irreversible BMX Inhibitor for the Treatment of Myocardial Hypertrophy and Remodeling. ACS Chem Biol, 2025 20 (6), 1181-1194.

Hypocrellin A from an ethnic medicinal fungus protects against NLRP3-driven gout in mice by suppressing inflammasome activation, Acta Pharmacologica Sinica, 2025, 46(4): 1016-1029.

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers. Acta Pharmacol Sin., 2022, 43, pages2678–2686.

Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia, 2022, 36, pages1048–1057.

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. J. Med.Chem., 2021, 64, 20, 15170–15188.

Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. J. Med. Chem. 2019, 62 (13), 6083-6101.

Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. Eur. J. Med. Chem. 2018 Mar 12;150:366-384.

专利

吡唑衍生物及其用途，2020-08-14，202010816805.9

MST1激酶抑制剂及其用途，2019-09-25，201910914334.2

MST1激酶抑制剂及其用途，2018-10-15，201811190756.1

吲唑类激酶抑制剂及其用途，2018-11-02，201811299323.X

一类新型的苯氧基哌啶衍生物及其用途，2018-03-19，201810224206.0

一种新型的PDGFR激酶抑制剂及其用途，2016-09-08，201610811854.7

一种选择性的C-KIT激酶抑制剂，2016-04-01，201610210424.X

一种新型布鲁顿酪氨酸激酶不可逆抑制剂，2016-02-04，201610084082.1

承担项目

mTOR/MNK双重抑制剂CYF-1-56克服mTOR抑制剂诱导的eIF4E活化导致的 耐药机制初探，国家自然科学基金青年项目，2020.01-2022.12，结题，主持

新型高活性高选择性FGF2/FGFR1配体陷阱蛋白抑制剂的理性设计和构效，安徽省自然科学基金面上项目，2019.07-2022.06，结题，主持

高选择性FGF1/FGFR信号通路配体陷阱大分子蛋白抑制剂的发现以及作用机制研究，院长基金青年“火花”项目，2018.06-2020.05，结题，主持